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Augmentation of Cutaneous Wound
Healing by Pharmacologic Mobilization
of Endogenous Bone Marrow Stem
Cells
Jakub Tolar1 and John A. McGrath2
Novel therapeutic tools to accelerate wound healing would have a major impact
on the overall burden of skin disease. Lin et al. demonstrate in mice that
endogenous bone marrow stem cell mobilization, produced by a pharmacologic
combination of AMD3100 and tacrolimus, leads to faster and better-quality
wound healing, findings that have exciting potential for clinical translation.
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Wound healing can be improved by using
medications already in clinical use to
mobilize endogenous bone marrow cells
There have been thorough and acceler-
ated efforts to improve skin wound
healing. These endeavors have been
motivated by the disappointing out-
comes of standard care for individuals
with extensive burns, diabetic and pres-
sure ulcers, and disfiguring scarring.
In this issue, Lin et al. (2014) take an
important step forward in the develop-
ment of a robust and widely applicable
treatment for cutaneous defects. They
report on a novel approach for boosting
the innate healing potential by which
blood cells are mobilized and engaged
in productive skin repair. What is
remarkable, significant, and new is that
their strategy engages lymphohemato-
poietic cells in skin repair by repur-
posing medications that are already in
use in clinical medicine.
Pedigree of ideas
All tissues are endowed with the capa-
city to repair themselves. However, they
differ greatly in the degree of injury that
they can withstand—with the peripheral
and central nervous systems able to
recover from only relatively small
insults, and with cutaneous and hema-
topoietic systems able to restore their
functions even after major injury.
Skin and bone marrow, however, do
not heal in the same way. Skin wounds
heal through a tightly orchestrated
sequence of skin stem cell activation,
with keratinocyte migration to, and
re-epithelialization of, the wound. By
contrast, reconstitution of the whole
lymphohematopoietic system is, in prin-
ciple, possible from a single hemato-
poietic stem cell. Thus, it has long been
believed that the major difference
between these two highly reparative
organ systems was that local mechan-
isms were operational in mucocuta-
neous tissue repair (after trauma, burn,
or surgical incision), whereas systemic
mechanisms regenerated hematopoiesis
(after viral infection, or whole-body
irradiation or chemotherapy in prepa-
ration for bone marrow transplantation).
The clinical utility of both drugs
used in the current study has been
proven in the practice of transplantation.
AMD3100 is used to release bone mar-
row cells into the peripheral blood,
where hematopoietic progenitors can
be collected and used in either auto-
logous or allogeneic hematopoietic cell
transplantation (Figure 1). Like the
closely related drug cyclosporine, tacro-
limus has been widely used to prevent
and treat rejection of solid-organ trans-
plants, as well as the major immune
complication of allogeneic hematopoie-
tic cell transplantation: graft-versus-host
disease. The mechanisms of action are
different. AMD3100 interferes with the
interaction of the CXC chemokine
receptor 4 (CXCR4) and its ligand
CXC motif chemokine 12 (CXCL12)
between hematopoietic and stromal
cells in the bone marrow (and other
tissues). Tacrolimus, on the other hand,
is a calcineurin inhibitor that (in much
higher doses than used in the
current study) inhibits calcium-depen-
dent T-cell activation and expansion.
Of interest, repurposing a calcineurin
inhibitor from an immunosuppre-
ssive agent to an endogenous stem cell
mobilizer (CD133þ hematopoietic and
endothelial progenitor cells in this
study) has been done before: cyclospor-
ine was first investigated as an
antifungal antibiotic in the early 1970s
(Borel, 1986).
The study by Lin et al. (2014) builds
upon a history of ideas, but especially
on the elegant work of Tamai et al.
(2011), who discovered a naturally
occurring bone marrow cell mobilizer
(high-mobility group box 1 protein) and
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its ability to attract bone marrow cells
(platelet-derived growth factor receptor
alpha–expressing mesenchymal stromal
cells) into injured epithelia. Recent
experimentation that illuminated the
local and systemic regenerative path-
ways showed that systemically adminis-
tered bone marrow cells migrate to
injured skin and contribute to its repair
(Woodley et al., 2007; Chino et al.,
2008; Tolar et al., 2009; Fujita et al.,
2010).
Regenerative dermatology
Every decade in the history of biomedi-
cine has a major theme that defines it,
for example, the discovery of antibiotics
in the 1930s, the breakthrough under-
standing of the DNA structure in
the 1950s, and the achievement of
whole-genome sequencing in the
1990s. The decades surrounding the
year 2020 are likely to be defined by
regenerative medicine. Near objectives,
such as cell therapy for myocardial
ischemia, stroke, and spinal cord injury,
are being addressed, and in the future
we may see the expanding societal
needs defined by more distant objec-
tives, such as recruitment of endogenous
repair mechanisms in the prevention or
therapy of neurodegenerative disease,
and preservation, restoration of function,
and even reversal of physiological aging.
Very few articles have
the potential to change
clinical practice; this
one does.
Related to this and the current work of
Lin et al. (2014), a number of new
questions arise where previously there
was only one: how is the declining
functionality of the immune system
(immunosenescence) going to impact
the applicability of the AMD3100 plus
tacrolimus treatment regimen in people
with diabetic or pressure ulcers—typi-
cally presenting as a consequence of
aging in the first place? Are the mobi-
lized endogenous cells fully polyclonal
or are they specific CD133þ clones
preferentially expanded and integrated
into skin healing? Does this approach
change the availability of CXCR4
(CD184) ligand, stromal cell-derived
factor 1 (CXCL12 chemokine)? How are
stromal and endothelial cells in bone
marrow and skin synchronously modu-
lated, for example, via the CXCR4/
CXCL12 chemoattractant pathway and
via vascular cell adhesion protein 1
(VCAM 1)/very late antigen 4 (VLA4)
adhesion pathway, respectively? There
is much more to be learned about the
interaction of skin autonomous and skin
nonautonomous cells, and, as always,
the firm foundation of clinical innova-
tion in mechanism-driven basic biology
is essential (Comroe and Dripps, 1976).
For example, it is unlikely that the
approach suggested here by Lin et al.
will apply to all skin injuries. Thus, to fix
skin wounds of various kinds, we need
to understand the short-range (epidermis
and dermis) and long-range (bone
marrow, lymph nodes, spleen, thymus)
signals characteristic of specific acute and
chronic skin conditions, the determinants
of the cell fate of blood and bone marrow
cells in skin, their ability to integrate in
skin niches and structures, their epi-
genetic memory, phenotype switching,
and capacity for tissue renewal.
Very few articles have the potential to
change clinical practice; this one does.
The safety profiles of AMD3100 and
low-dose tacrolimus are well known
and—although the safety of long-term,
repeated administration in the setting
of specific systemic comorbidity (such
as diabetes mellitus, coagulopathy,
and immobilization) needs to be estab-
lished—it is probable, even likely, that
the preclinical evidence is substantial
enough to justify carefully designed
clinical trials in those individuals who
Clinical Implications
 Endogenous lymphohematopoietic stem cells can enhance the speed and
quality of wound healing, including restoration of skin architecture and
hair follicles.
 Systemic use of two clinically approved drugs, AMD3100 and tacrolimus,
can mobilize and recruit these reparative stem cells to damaged skin.
 The clinical management of impaired wound healing and perhaps other
skin pathologies (including aging) could be transformed by the findings of
Lin et al.
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Figure 1. Better and faster skin wound healing achieved by combined action of AMD3100 and
tacrolimus. AMD3100 releases bone marrow cells into the peripheral blood, while tacrolimus inhibits
calcium-dependent T-cell activation and expansion. This novel approach for boosting innate healing
potential, in which blood cells are mobilized and engaged in productive skin repair, is further evidence of
systemically administered bone marrow cells migrating to injured skin and contributing to its repair.
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currently receive only palliative care
and in whom potential benefits out-
weigh potential risks.
At the same time, this study immedi-
ately suggests an optimization strategy
for individuals with life-threatening gen-
odermatoses (such as severe generalized
forms of recessive dystrophic epidermo-
lysis bullosa and junctional epidermoly-
sis bullosa) who have already received
blood and bone marrow transplantation
from immunologically matched related
or unrelated healthy donors. The major-
ity of these children have lasting and
significant improvement in mucocuta-
neous integrity and quality of life, but
none has had a complete resolution of
all lesions. Typically, a few small ero-
sions persist, even years after allogeneic
hematopoietic cell transplantation
(Wagner et al., 2010; Tolar and
Wagner, 2013). Mobilization of wild-
type cells engrafted in their bone
marrow using the synergistic action of
AMD3100 and tacrolimus could
increase the effective CD133þ cell
dose in the remaining skin lesions and,
if successful, establish a new paradigm
for combination therapy in augmenting
wound healing and improving skin
function.
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